CLEMEDI

Clemedi develops in vitro diagnostic tests for infectious diseases, by uniting two novel technologies – Next-generation Sequencing and Machine learning. They will contribute to limiting deaths caused by antibiotic resistant bacteria, projected to reach 10 million annually in 2050! Our diagnostic tests support doctors’ decision-making by enabling him or her to give a timely and personalized antibiotic therapy. Ultimately, patients suffering from infectious diseases will benefit with their product.